Abstract
Breast cancer continues to be a significant health problem, with an annual incidence of over 1.7 million and annual mortality of 500,000 world-wide. Breast cancer remains one of the most common causes of cancer death in developed countries and its incidence in developing countries has been trending upward, becoming a major health burden in these countries, as well.
A tremendous amount of research has been devoted to understanding the causes of breast cancer and to developing new therapies for this disease. This broad-based effort has resulted in definition of multiple molecular pathways that contribute to the development of breast cancer. This body of information is being used to develop new assessments and therapies that are improving both the survival and the quality of life of breast cancer patients. In this chapter we review the molecular biology of breast cancer, its pathological assessment and diagnosis, and methods for risk stratification. The current methods for local and systemic treatment, incluing surgical management and adjuvant therapy are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
International Agency for Research on Cancer. GLOBOCAN (2008) Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. Available from: http://globocan.iarc.fr/
Forouzanfar MH et al (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801):1461–1484
Cancer Facts and Figures (2013) Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index
Leong SL et al (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34(10):2308–2324
Abdulrahman GO, Rahman GA (2012) Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012:5
Ferlay J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (Oxford, England: 1990) 49(6):1374–1403
Chen WQ et al (2013) Incidence and mortality of breast cancer in China, 2008. Thorac Cancer 4(1):59–65
Radford DM, Zehnbauer BA (1996) Inherited breast cancer. Surg Clin North Am 76(2):205–220
Maxwell KN, Nathanson KL (2013) Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res 15(6):212
CGAN (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
Curtis C et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352
Zheng S et al (2012) The pathologic characteristics of breast cancer in China and its shift during 1999–2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer 131(11):2622–2631
Alexander DD et al (2010) Summary and meta-analysis of prospective studies of animal fat intake and breast cancer. Nutr Res Rev 23(1):169–179
Chlebowski RT et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 289(24):3243–3253
Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15(1):48–65
Rosner B, Colditz GA, Willett WC (1994) Reproductive risk factors in a prospective study of breast cancer: the Nurses’ Health Study. Am J Epidemiol 139(8):819–835
Love RR, Philips J (2002) Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 94(19):1433–1434
Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276(40):36869–36872
Slamon D et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
Thery JC et al (2014) Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 50(5):892–901
Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119
Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171–182
Fong PC et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134
Weinberg RA (2007) The biology of cancer. Garland Science, New York
Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136(5):823–837
Wood LD et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853):1108–1113
Magbanua MJ et al (2012) Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 12(1):78
Copeland NG, Jenkins NA (2009) Deciphering the genetic landscape of cancer – from genes to pathways. Trends Genet 25(10):455–462
Kreeger PK, Lauffenburger DA (2010) Cancer systems biology: a network modeling perspective. Carcinogenesis 31(1):2–8
Veeck J, Esteller M (2010) Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 15(1):5–17
Fiskus W et al (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13(16):4882–4890
Perou CM et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96(16):9212–9217
Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874
Esserman LJ et al (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132(3):1049–1062
Paik S (2011) Is gene array testing to be considered routine now? Breast 20(Suppl 3):S87–S91
Bartlett JMS et al (2012) Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol 30(36):4477–4484
Zou H et al (2007) Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 16(12):2686–2696
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410
Relf M et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969
Fang H, DeClerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73(16):4965–4977
Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51
Janakiram M et al (2012) T cell coinhibition and immunotherapy in human breast cancer. Discov Med 14(77):229–236
Stagg J, Allard B (2013) Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 5(3):169–181
Onishi T et al (2010) Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641–651
Kösters JP, Gøtzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003373
U.S.P.S.T.F. (2009) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151(10):716–726, W-236
Tabar L et al (2001) Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 91(9):1724–1731
Nelson HD et al (2009) Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151(10):727–737, W237-42
Bruening W et al (2012) Noninvasive diagnostic tests for breast abnomalities, vol 47, Comparative effectiveness reviews. Agency for Healthcare Research and Quality (US), Rockville
Burstein HJ, Harris JR, Morrow M (2011) Malignant tumors of the breast. In: De Vita VT, Lawrence TS, Roseberg SA (eds) Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, Philadelphia, pp 1401–1446
Hindle WH (1999) Development and growth of the breast. In: Hindle WH, MD (eds) Breast care. Springer, New York, pp 28–39
Lester S, Cotran R (1999) The breast. In: Cotran R, Kumar V, Collins T (eds) Pathologic basis of disease. W.B. Saunders Company, Philadelphia, pp 1093–1119
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410
Guidance for Industry and Food and Drug Administration Staff – In Vitro Companion Diagnostic Devices (2011) [cited 2014 January 21]; Draft guidance on companion diagnostic development]
Allred DC (2010) Issues and updates: evaluating estrogen receptor-[alpha], progesterone receptor, and HER2 in breast cancer. Mod Pathol 23(S2):S52–S59
Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013
Edge S et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
Gradishar WJ et al (2014) NCCN clinical practice guidelines in oncology: breast cancer. Version 2.2014
Fisher B et al (1985) Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312(11):674–681
Suyoi A et al (2014) When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node? Eur J Cancer 50(4):690–697
Giuliano AE et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575
Tokin C et al (2012) Oncologic safety of skin-sparing and nipple-sparing mastectomy: a discussion and review of the literature. Int J Surg Oncol 2012:921821
EBCTCG (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716
Moran MS et al (2014) Society of Surgical Oncology-American Society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol 21(3):704–716
Akyurek S, Yavas G (2013) Role of postmastectomy radiation therapy after neoadjuvant chemotherapy in locally advanced breast cancer. Exp Oncol 35(4):267–271
Yang TJ, Ho AY (2013) Radiation therapy in the management of breast cancer. Surg Clin North Am 93(2):455–471
Whelan TJ et al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520
Badwe R, Parmar V, Hawaldar R (2013) Surgical removal of primary tumor and axillary lymph nodes in women metastatic breast cancer at first presentation: a randomized controlled trial. In San Antonio breast cancer symposium, San Antonio, Abstract, pp S2–02
Virnig BA et al (2009) Diagnosis and management of ductal carcinoma in situ (DCIS). Evid Rep Technol Assess (Full Rep) 185:1–549
McLaughlin SA (2013) Surgical management of the breast: breast conservation therapy and mastectomy. Surg Clin North Am 93(2):411–428
Wapnir IL et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488
Masannat YA et al (2013) Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast 22(2):194–196
O’Malley FP (2010) Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol 23(Suppl 2):S14–S25
Bramati A et al (2014) Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev 40(5):605–613
Clark O et al (2014) Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid 9:1–11
André F, Zielinski CC (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23(suppl 6):vi46–vi51
Yang LH et al (2012) Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer 15(3):288–295
Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388
Visvanathan K et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(23):2942–2962
Dickler MN, Norton L (2001) The MORE trial: multiple outcomes for raloxifene evaluation – breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 949:134–142
Barrett-Connor E et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355(2):125–137
Siris ES et al (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20(9):1514–1524
Vogel VG (2009) The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 9(1):51–60
den Hollander P, Savage MI, Brown PH (2013) Targeted therapy for breast cancer prevention. Front Oncol 3:250
Swaby RF, Sharma CG, Jordan VC (2007) SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 8(3):229–239
Burstein HJ et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796
Chia S et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664–1670
Johnston SR et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989–998
Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
Pivot X et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748
Pogue-Geile KL et al (2013) Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 105(23):1782–1788
Freedman RA, Muss HB (2014) Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. J Geriatr Oncol 5(1):2–7
Goldhirsch A et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028
Rayson D et al (2008) Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 19(9):1530–1539
Buzdar AU et al (2013) Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 14(13):1317–1325
Robidoux A et al (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 14(12):1183–1192
Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
Incorvati JA et al (2013) Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 6:38
Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471
Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791
Sendur MA, Aksoy S, Altundag K (2013) Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29(8):1015–1024
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schuur, E.R., DeAndrade, J.P. (2015). Breast Cancer: Molecular Mechanisms, Diagnosis, and Treatment. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-21683-6_9
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21682-9
Online ISBN: 978-3-319-21683-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)